# SOLIGENIX, INC. (SNGX) · Edgar & Edgarette company card

> Soligenix, Inc. (SNGX) saw revenue fall 85.8% in FY2024 to $0 million, operating margin -7908% against a -3.8% median for pharmaceutical preparations, equity 45.9% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 812796 · fiscal year ended 2024-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/SNGX) · [JSON](https://www.pops4.com/boards/company/SNGX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $119,371 |
| Revenue growth, 1 year | -85.8% |
| Revenue growth per year | -52.6% |
| Operating margin | -7907.7% (prior year -917.1%) |
| Net margin | -6925.1% |
| Operating cash flow | −$8M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $8M |
| Long-term debt | $0 |
| Total assets | $9M |
| Total equity | $4M |
| Equity ÷ assets | 45.9% |
| Return on equity | -200.7% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -88.34 (distress zone)
- Piotroski F: 2 of 9 (weak)
- Health Harbor boat: Weathered boat · two warning signs · operating cash flow was negative (-$10.3M in FY2025); revenue is hard to predict: its 80% range is ±67%

## Edgarette's reading

Exposure: revenue $119K (FY2024), total debt $0K. Experience: revenue down 85.8% on the year, down 52.6% a year over 4 years; operating margin -7907.7%, down from -917.1%. Soundness: equity 45.9% of assets, return on equity -200.7%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $17K and $88K next year (method v4.1: its own 5-year record of growth weighed at 57% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $16K to $99K. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -7907.7% against a -3.8% median; growth -85.8% against 13.7%.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 2, latest 2026-06-12 ([filing](https://www.sec.gov/Archives/edgar/data/812796/000110465926073430/0001104659-26-073430-index.htm))
- Item 5.02 Director or officer change: 1, latest 2026-06-12 ([filing](https://www.sec.gov/Archives/edgar/data/812796/000110465926073430/0001104659-26-073430-index.htm))

## Recent filings

- 10-Q · filed 2026-11-06 · [filing](https://www.sec.gov/Archives/edgar/data/812796/000110465926123855/0001104659-26-123855-index.htm)
- 8-K · filed 2026-09-21 · 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/812796/000110465926109329/0001104659-26-109329-index.htm)
- 10-Q · filed 2026-08-07 · [filing](https://www.sec.gov/Archives/edgar/data/812796/000110465926092681/0001104659-26-092681-index.htm)
- DEF 14A · filed 2026-08-03 · [filing](https://www.sec.gov/Archives/edgar/data/812796/000110465926089789/0001104659-26-089789-index.htm)
- 8-K · filed 2026-06-26 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/812796/000110465926078251/0001104659-26-078251-index.htm)
- 8-K · filed 2026-06-12 · 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule; 5.02 Departure or Election of Directors; Appointment of Officers; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/812796/000110465926073430/0001104659-26-073430-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000812796.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=812796

## Cite

POPS4, Edgar & Edgarette: SOLIGENIX, INC. (SNGX) company card, from the company's own SEC filings, accessed 2026-11-06, https://www.pops4.com/boards/company/SNGX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Its latest audited year is FY2025, which reports no revenue; the revenue figures and the range here are from FY2024, its last year with revenue on record. Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.